Latest & greatest articles for doxazosin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on doxazosin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on doxazosin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for doxazosin

1. Doxazosin

Doxazosin Top results for doxazosin - Trip Database or use your Google+ account Liberating the literature My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing (...) the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for doxazosin The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines

Trip Latest and Greatest2018

2. Effect of 8-Week Combination Therapy with an Extended-Release α1-Blocker (Bunazosin or Doxazosin) in Inadequate Responders to an Angiotensin II Antagonist (Valsartan) in Patients with Stage 1 or 2 Essential Hypertension.

Effect of 8-Week Combination Therapy with an Extended-Release α1-Blocker (Bunazosin or Doxazosin) in Inadequate Responders to an Angiotensin II Antagonist (Valsartan) in Patients with Stage 1 or 2 Essential Hypertension. 27122680 2016 04 28 2016 04 28 2017 02 20 1011-6842 29 1 2013 Jan Acta Cardiologica Sinica Acta Cardiol Sin Effect of 8-Week Combination Therapy with an Extended-Release α1-Blocker (Bunazosin or Doxazosin) in Inadequate Responders to an Angiotensin II Antagonist (Valsartan (...) ) in Patients with Stage 1 or 2 Essential Hypertension. 11-8 Given the favorable impact of α1-blockers on lipid and glucose metabolism, this study was designed to compare the efficacy of two extended-release α1-blockers (bunazosin and doxazosin) as an add-on treatment in subjects with stage 1 or 2 essential hypertension which was inadequately controlled by valsartan 80 mg/day. After a 5-week treatment of valsartan monotherapy, subjects with inadequately controlled hypertension were randomized to receive

Zhonghua Minguo xin zang xue hui za zhi = Acta Cardiologica Sinica2016

3. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.

Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. BACKGROUND: Optimal drug treatment for patients with resistant hypertension is undefined. We aimed to test the hypotheses that resistant hypertension is most often caused by excessive sodium retention, and that spironolactone would therefore be superior to non-diuretic add-on drugs at lowering blood (...) weeks of once daily treatment with each of spironolactone (25-50 mg), bisoprolol (5-10 mg), doxazosin modified release (4-8 mg), and placebo, in addition to their baseline blood pressure drugs. Random assignment was done via a central computer system. Investigators and patients were masked to the identity of drugs, and to their sequence allocation. The dose was doubled after 6 weeks of each cycle. The hierarchical primary endpoints were the difference in averaged home systolic blood pressure between

Lancet2015

4. An economic evaluation of doxazosin, finasteride and combination therapy in the treatment of benign prostatic hyperplasia

An economic evaluation of doxazosin, finasteride and combination therapy in the treatment of benign prostatic hyperplasia An economic evaluation of doxazosin, finasteride and combination therapy in the treatment of benign prostatic hyperplasia An economic evaluation of doxazosin, finasteride and combination therapy in the treatment of benign prostatic hyperplasia McDonald H, Hux M, Brisson M, Bernard L, Nickel J C Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined finasteride (FIN), a 5-alpha-reductase inhibitor, either alone or in combination with doxazosin (DOX), an alpha-blocker, for the treatment of benign prostate hyperplasia (BPH). The doses used were 5 mg FIN once daily and 4 mg DOX once daily. Type

NHS Economic Evaluation Database.2004

5. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.

The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. 14681504 2003 12 18 2003 12 23 2013 11 21 1533-4406 349 25 2003 Dec 18 The New England journal of medicine N. Engl. J. Med. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. 2387-98 Benign prostatic hyperplasia is commonly treated with alpha-adrenergic-receptor antagonists (alpha (...) -blockers) or 5alpha-reductase inhibitors. The long-term effect of these drugs, singly or combined, on the risk of clinical progression is unknown. We conducted a long-term, double-blind trial (mean follow-up, 4.5 years) involving 3047 men to compare the effects of placebo, doxazosin, finasteride, and combination therapy on measures of the clinical progression of benign prostatic hyperplasia. The risk of overall clinical progression--defined as an increase above base line of at least 4 points

NEJM2003

6. The cost-effectiveness of doxazosin for the treatment of hypertension in type II diabetic patients in the UK and Italy

The cost-effectiveness of doxazosin for the treatment of hypertension in type II diabetic patients in the UK and Italy The cost-effectiveness of doxazosin for the treatment of hypertension in type II diabetic patients in the UK and Italy The cost-effectiveness of doxazosin for the treatment of hypertension in type II diabetic patients in the UK and Italy Casciano J, Doyle J, Casciano R, Kopp Z, Marchant N, Bustacchini S, Arikian S, Kim R Record Status This is a critical abstract of an economic (...) evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of doxazosin for the treatment of hypertension in Type II diabetes. Type of intervention Treatment and prevention. Economic study type Cost-effectiveness analysis. Study population The study population comprised patients

NHS Economic Evaluation Database.2001

7. New Drugs VI ? Rosiglitazone (Avandia®), Tolterodine (Detrol®), Bupropion (Wellbutrin SR®, Zyban®), Doxazosin (Cardura®)

New Drugs VI ? Rosiglitazone (Avandia®), Tolterodine (Detrol®), Bupropion (Wellbutrin SR®, Zyban®), Doxazosin (Cardura®) [44] New Drugs VII – Mirtazapine (Remeron®), Salmon-Calcitonin Nasal Spray (Miacalcin®), Gatifloxacin (Tequin®), Moxifloxacin | Therapeutics Initiative Independent Healthcare Evidence > > [44] New Drugs VII – Mirtazapine (Remeron®), Salmon-Calcitonin Nasal Spray (Miacalcin®), Gatifloxacin (Tequin®), Moxifloxacin Mirtazapine (Remeron ® ) Approved indication: “Symptomatic

Therapeutics Letter2000

8. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.

Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. 10789664 2000 05 04 2000 05 04 2016 10 17 0098-7484 283 15 2000 Apr 19 JAMA JAMA Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT (...) Collaborative Research Group. 1967-75 Hypertension is associated with a significantly increased risk of morbidity and mortality. Only diuretics and beta-blockers have been shown to reduce this risk in long-term clinical trials. Whether newer antihypertensive agents reduce the incidence of cardiovascular disease (CVD) is unknown. To compare the effect of doxazosin, an alpha-blocker, with chlorthalidone, a diuretic, on incidence of CVD in patients with hypertension as part of a study of 4 types

JAMA2000